AI assistant
Sending…
InMed Pharmaceuticals Inc. — Director's Dealing 2022
Dec 16, 2022
35386_dirs_2022-12-15_0e995159-abc3-4f99-a4b6-3784e81f2ef4.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: InMed Pharmaceuticals Inc. (INM)
CIK: 0001728328
Period of Report: 2022-12-12
Reporting Person: Tegge Jonathan (Interim CFO)
More from InMed Pharmaceuticals Inc.
Regulatory Filings
2026
May 19
Regulatory Filings
2026
May 19
Interim / Quarterly Report
2026
May 6
Capital/Financing Update
2026
Apr 3
Capital/Financing Update
2026
Apr 3
Regulatory Filings
2026
Mar 23
Regulatory Filings
2026
Mar 20
Earnings Release
2026
Feb 12
Interim / Quarterly Report
2026
Feb 11
Major Shareholding Notification
2026
Jan 20